NCT07007312 2026-04-09
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
Clinical Trials
7 trialsNCT03173248 2025-11-10
AGILE
Servier
Phase 3 Active not recruiting
NCT07082452 2025-07-24
SEVENAZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Not yet recruiting
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT04090736 2025-03-17
PEVOLAM
PETHEMA Foundation
Phase 3 Active not recruiting
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT00887068 2020-01-14
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
M.D. Anderson Cancer Center
Phase 3 Completed